NCT00615693

Safety, Tolerability, and Efficacy of AEB071 in the Treatment of Uveitis

A Multicenter, Single Sequence, Open-label Study to Assess the Tolerability, Safety, and Efficacy of 2 Weeks Oral AEB071 300 mg Twice Daily, Followed by 6 Weeks AEB071 200 mg Twice Daily in the Treatment of Patients With Macular Edema Associated With Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 13 (actual)
• Sponsor: Novartis · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the safety, tolerability, and efficacy of AEB071 as a therapy for uveitis. Vision improvement and reduction in the swelling of retina will be measured for the assessment of efficacy.

Conditions

• Uveitis
• Posterior Uveitis
• Panuveitis

Interventions

Type	Name	Description
DRUG	AEB071

Timeline

• Start date: 2008-07-01
• Primary completion: 2009-10-01
• First posted: 2008-02-14
• Last updated: 2020-12-22

Locations

13 sites across 1 country: United States